This page contains exclusive content for the member of the following sections: TTS. Log in to view.
Presenter: Iain, MacPhee, London,
Authors: Moreton M., Junior E., Holt D., MacPhee I.
CLINICAL IMMUNOSUPPRESSION - KIDNEY LATE
M. Moreton1, E. Junior1, D.W. Holt1, I.A.M. Macphee2
1Cardiac And Vascular Sciences: Analytical Unit, St. George's, University of London, London/UNITED KINGDOM, 2Cellular And Molecular Medicine: Renal Medicine, St. George's, University of London, London/UNITED KINGDOM
Body: Introduction: CYP3A5 genotype has been shown to have a major and the ABCB1 genotype to have a minor influence on the dose-requirement for tacrolimus. Data for sirolimus are less clear, with a likely influence of the CYP3A5 genotype and no positive reports of an association with the ABCB1 genotype. Methods: A sub-group of patients from a multi-centre randomized controlled trial of switching patients from calcineurin inhibitor therapy to sirolimus at least 6 months after renal transplantation consented to entry to a pharmacogenetic sub-study. Calcineurin inhibitor was discontinued and on the next day a loading dose of 12 mg sirolimus was given followed by 4 mg daily. The dose was then adjusted to a target blood concentration of 8-16 ng/mL. The study received ethical approval and subjects gave written informed consent. Results: Of the 47 patients recruited there were 5 CYP3A5 expressers. Associations with the ABCB1 genotype were only apparent after exclusion of the CYP3A5 expressers. The data presented are for the 42 CYP3A5 non-expressers. Median time post-transplant was 4.3 years (range 0.6-17.8); 11 were female and 31 male; median age was 44 years (range 26-71). Ethnic groups: 2 Asian, 39 Caucasian and 1 other. Values shown in the table are median (interquartile range) for dose normalized sirolimus blood concentration (ng/mL/mg/kg) on day 4 after switch to sirolimus. Exposure was significantly lower for heterozygotes at the 3435C>T SNP (Kruskal-Wallis p=0.006) and when TT homozygotes were compared to the other groups for the 1236C>T SNP (Mann-Whitney p=0.025).
SNP | CC or GG | CT or GT/GA | TT | p |
1236C>T (Exon 12) | 212(172-263) | 186(152-271) | 291(227-379) | NS |
2677g>(T,A) (Exon 21) | 178(154-237) | 237(174-318) | 224(170-266) | NS |
3435C>T (Exon 26) | 264(187-322) | 171(148-214) | 301(243-377) | 0.006 |
Disclosure: All authors have declared no conflicts of interest.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada